Prothena Corporation PLC Company Profile (NASDAQ:PRTA)

About Prothena Corporation PLC (NASDAQ:PRTA)

Prothena Corporation PLC logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PRTA
  • CUSIP: N/A
  • Web: www.prothena.com
Capitalization:
  • Market Cap: $2.09 billion
  • Outstanding Shares: 38,275,000
Average Prices:
  • 50 Day Moving Avg: $60.67
  • 200 Day Moving Avg: $55.15
  • 52 Week Range: $40.58 - $69.53
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.70
  • P/E Growth: 0.75
Sales & Book Value:
  • Annual Revenue: $27.53 million
  • Price / Sales: 75.90
  • Book Value: $12.76 per share
  • Price / Book: 4.28
Profitability:
  • EBIDTA: ($135,600,000.00)
  • Net Margins: -527.56%
  • Return on Equity: -33.20%
  • Return on Assets: -27.66%
Debt:
  • Current Ratio: 12.93%
  • Quick Ratio: 12.93%
Misc:
  • Average Volume: 294,348 shs.
  • Beta: 2.59
  • Short Ratio: 22.03
 

Frequently Asked Questions for Prothena Corporation PLC (NASDAQ:PRTA)

What is Prothena Corporation PLC's stock symbol?

Prothena Corporation PLC trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena Corporation PLC's earnings last quarter?

Prothena Corporation PLC (NASDAQ:PRTA) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.46) EPS for the quarter, topping the Zacks' consensus estimate of ($0.89) by $0.43. The firm earned $26.81 million during the quarter, compared to analyst estimates of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The company's revenue was up 7951.1% on a year-over-year basis. During the same period last year, the company earned ($1.18) earnings per share. View Prothena Corporation PLC's Earnings History.

When will Prothena Corporation PLC make its next earnings announcement?

Prothena Corporation PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Prothena Corporation PLC.

Where is Prothena Corporation PLC's stock going? Where will Prothena Corporation PLC's stock price be in 2017?

12 brokerages have issued 12-month target prices for Prothena Corporation PLC's stock. Their predictions range from $65.00 to $100.00. On average, they anticipate Prothena Corporation PLC's share price to reach $78.64 in the next year. View Analyst Ratings for Prothena Corporation PLC.

What are analysts saying about Prothena Corporation PLC stock?

Here are some recent quotes from research analysts about Prothena Corporation PLC stock:

  • 1. According to Zacks Investment Research, "The narrower-than-expected loss in the second quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. Prothena recently earned a $30 million of milestone payment from Roche. The company’s shares have outperformed the industry in the past one year. We expect investor focus to remain on further updates from its late-stage candidate, NEOD001. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (8/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Sticking to their knitting. In prior experience, PRTA scientists developed monoclonal antibodies (MAbs) bapineuzumab and natalizumab (Tysabri) that targeted misfolded protein (beta amyloid) and prevented T cell trafficking, respectively." (4/12/2017)
  • 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)

Who are some of Prothena Corporation PLC's key competitors?

Who are Prothena Corporation PLC's key executives?

Prothena Corporation PLC's management team includes the folowing people:

  • Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board
  • Gene G. Kinney Ph.D., President, Chief Executive Officer, Director
  • Tran B. Nguyen, Chief Financial Officer
  • Karin L. Walker CPA, Chief Accounting Officer, Controller
  • Wagner Zago, Chief Scientific Officer
  • Arthur W. Homan, Chief Legal Officer
  • Carol D. Karp, Chief Regulatory Officer
  • Martin Koller M.D., Chief Medical Officer
  • Tara Nickerson Ph.D., Chief Business Officer
  • K. Anders O. Harfstrand M.D., Ph.D., Director

Who owns Prothena Corporation PLC stock?

Prothena Corporation PLC's stock is owned by many different of institutional and retail investors. Top institutional investors include Woodford Investment Management Ltd (29.99%), FMR LLC (14.99%), BlackRock Inc. (7.75%), Capital World Investors (3.46%), State Street Corp (3.09%) and Palo Alto Investors LLC (2.81%). Company insiders that own Prothena Corporation PLC stock include Arthur W Homan, Christopher S Henney, Dale B Schenk, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Lars Ekman, Martin Koller, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena Corporation PLC.

Who sold Prothena Corporation PLC stock? Who is selling Prothena Corporation PLC stock?

Prothena Corporation PLC's stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Pioneer Investment Management Inc., Wells Fargo & Company MN, Northern Trust Corp, Pinnacle Associates Ltd., Oak Ridge Investments LLC, Parametric Portfolio Associates LLC and Turner Investments LLC. Company insiders that have sold Prothena Corporation PLC stock in the last year include Arthur W Homan, Dennis J Selkoe, Gene G Kinney and Karin L Walker. View Insider Buying and Selling for Prothena Corporation PLC.

Who bought Prothena Corporation PLC stock? Who is buying Prothena Corporation PLC stock?

Prothena Corporation PLC's stock was bought by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Woodford Investment Management Ltd, PointState Capital LP, BlackRock Inc., State Street Corp, Alliancebernstein L.P., Sphera Funds Management LTD. and FMR LLC. View Insider Buying and Selling for Prothena Corporation PLC.

How do I buy Prothena Corporation PLC stock?

Shares of Prothena Corporation PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prothena Corporation PLC's stock price today?

One share of Prothena Corporation PLC stock can currently be purchased for approximately $54.59.


MarketBeat Community Rating for Prothena Corporation PLC (NASDAQ PRTA)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Prothena Corporation PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Prothena Corporation PLC (NASDAQ:PRTA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 12 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $78.64 (44.05% upside)

Analysts' Ratings History for Prothena Corporation PLC (NASDAQ:PRTA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$83.00HighView Rating Details
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$100.00MediumView Rating Details
7/6/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$70.00LowView Rating Details
5/19/2017BTIG ResearchInitiated CoverageBuy$80.00HighView Rating Details
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMediumView Rating Details
4/12/2017Cantor FitzgeraldInitiated CoverageOverweight$86.00HighView Rating Details
4/3/2017WedbushReiterated RatingOutperform$77.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$87.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
12/20/2016SunTrust Banks, Inc.Initiated CoverageBuy$75.00N/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$73.00N/AView Rating Details
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/AView Rating Details
8/4/2016Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00N/AView Rating Details
7/18/2016Royal Bank Of CanadaReiterated RatingOutperform$95.00N/AView Rating Details
(Data available from 8/19/2015 forward)

Earnings

Earnings History for Prothena Corporation PLC (NASDAQ:PRTA)
Earnings by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Earnings History by Quarter for Prothena Corporation PLC (NASDAQ PRTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($1.41)N/AView Earnings Details
8/8/20176/30/2017($0.89)($0.46)$16.08 million$26.81 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.32)($0.99)$0.26 million$0.26 millionViewN/AView Earnings Details
2/14/2017Q416($1.12)($1.41)$5.35 million$0.20 millionViewListenView Earnings Details
11/1/2016Q3($1.22)($1.26)$0.49 million$0.29 millionViewN/AView Earnings Details
8/2/2016Q2($0.91)($1.18)$0.39 million$0.33 millionViewN/AView Earnings Details
5/3/2016Q116($0.77)($0.81)$0.27 million$0.27 millionViewN/AView Earnings Details
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details
11/2/2015($0.66)($0.73)$0.28 million$0.43 millionViewN/AView Earnings Details
8/4/2015Q2($0.56)($0.59)$0.60 million$0.28 millionViewN/AView Earnings Details
5/5/2015($0.59)($0.55)$1.95 million$0.59 millionViewN/AView Earnings Details
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details
8/4/2014Q214$0.06$15.17 million$15.12 millionViewN/AView Earnings Details
5/5/2014$0.81$0.78$30.17 million$32.23 millionViewN/AView Earnings Details
3/6/2014Q113($0.52)ViewN/AView Earnings Details
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Prothena Corporation PLC (NASDAQ:PRTA)
2017 EPS Consensus Estimate: ($5.08)
2018 EPS Consensus Estimate: ($4.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.42)($1.28)($1.36)
Q2 20174($1.20)($0.50)($0.87)
Q3 20174($1.54)($1.21)($1.36)
Q4 20174($1.77)($1.27)($1.49)
Q1 20181($1.27)($1.27)($1.27)
Q2 20181($1.24)($1.24)($1.24)
Q3 20181($1.08)($1.08)($1.08)
Q4 20181($0.99)($0.99)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Prothena Corporation PLC (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Prothena Corporation PLC (NASDAQ:PRTA)
Insider Ownership Percentage: 3.10%
Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Karin L WalkerInsiderSell5,000$64.89$324,450.00View SEC Filing  
7/7/2017Dennis J SelkoeDirectorSell3,500$58.11$203,385.00View SEC Filing  
4/17/2017Karin L WalkerInsiderSell5,000$52.25$261,250.00View SEC Filing  
4/3/2017Dennis J SelkoeDirectorSell3,500$55.86$195,510.00View SEC Filing  
3/9/2017Tran NguyenCFOBuy1,000$51.32$51,320.00View SEC Filing  
1/4/2017Arthur W HomanInsiderSell3,125$52.25$163,281.25View SEC Filing  
11/28/2016Dennis J SelkoeDirectorSell5,000$62.42$312,100.00View SEC Filing  
11/9/2016Gene G KinneyInsiderSell8,548$55.32$472,875.36View SEC Filing  
10/21/2016Gene G KinneyInsiderSell20,619$55.10$1,136,106.90View SEC Filing  
10/13/2016Karin L WalkerInsiderSell5,000$54.23$271,150.00View SEC Filing  
9/19/2016Karin L WalkerInsiderSell12,000$61.10$733,200.00View SEC Filing  
9/1/2016Arthur W HomanInsiderSell3,125$52.16$163,000.00View SEC Filing  
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Prothena Corporation PLC (NASDAQ:PRTA)
Latest Headlines for Prothena Corporation PLC (NASDAQ:PRTA)
Source:
DateHeadline
americanbankingnews.com logoProthena Corporation PLC (PRTA) Coverage Initiated at Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM
finance.yahoo.com logoProthena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting
finance.yahoo.com - August 16 at 6:57 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Prothena Corporation PLC Increased by Wedbush (NASDAQ:PRTA)
www.americanbankingnews.com - August 14 at 2:28 AM
americanbankingnews.com logoSunTrust Banks Comments on Prothena Corporation PLC's Q3 2017 Earnings (NASDAQ:PRTA)
www.americanbankingnews.com - August 14 at 2:28 AM
americanbankingnews.com logoProthena Corporation PLC (PRTA) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 13 at 2:24 PM
finance.yahoo.com logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : August 11, 2017
finance.yahoo.com - August 12 at 7:02 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Prothena Corporation PLC Lifted by Analyst (NASDAQ:PRTA)
www.americanbankingnews.com - August 11 at 8:12 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Prothena Corporation PLC Decreased by Analyst (NASDAQ:PRTA)
www.americanbankingnews.com - August 11 at 8:12 AM
nasdaq.com logoProthena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment - Nasdaq
www.nasdaq.com - August 11 at 7:46 AM
finanznachrichten.de logoProthena Corporation plc: Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update
www.finanznachrichten.de - August 10 at 7:02 AM
finance.yahoo.com logoProthena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment
finance.yahoo.com - August 10 at 7:02 AM
globenewswire.com logoProthena Reports Second Quarter 2017 Financial Results and Provides R&D Update - GlobeNewswire (press release)
globenewswire.com - August 9 at 6:34 AM
finance.yahoo.com logoProthena Reports Second Quarter 2017 Financial Results and Provides R&D Update
finance.yahoo.com - August 9 at 6:33 AM
finance.yahoo.com logoProthena reports 2Q loss
finance.yahoo.com - August 9 at 6:33 AM
americanbankingnews.com logoProthena Corporation PLC (NASDAQ:PRTA) Announces Earnings Results, Beats Expectations By $0.43 EPS
www.americanbankingnews.com - August 8 at 6:50 PM
nasdaq.com logoShould You Buy Prothena Corporation PLC (PRTA) Ahead of Earnings? - Nasdaq
www.nasdaq.com - August 8 at 6:22 AM
finance.yahoo.com logoShould You Buy Prothena Corporation PLC (PRTA) Ahead of Earnings?
finance.yahoo.com - August 8 at 6:22 AM
americanbankingnews.com logo Analysts Expect Prothena Corporation PLC (NASDAQ:PRTA) Will Post Quarterly Sales of $18.87 Million
www.americanbankingnews.com - August 7 at 7:06 AM
americanbankingnews.com logoProthena Corporation PLC (PRTA) Expected to Post Earnings of -$0.89 Per Share
www.americanbankingnews.com - August 5 at 7:14 AM
americanbankingnews.com logoProthena Corporation PLC (NASDAQ:PRTA) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 11:27 AM
finanznachrichten.de logoProthena Corporation plc: Prothena to Report Second Quarter 2017 Financial Results on August 8
www.finanznachrichten.de - August 2 at 6:50 AM
nasdaq.com logoProthena to Report Second Quarter 2017 Financial Results on August 8 - Nasdaq
www.nasdaq.com - August 2 at 6:50 AM
finance.yahoo.com logoProthena to Report Second Quarter 2017 Financial Results on August 8
finance.yahoo.com - August 2 at 6:50 AM
americanbankingnews.com logoProthena Corporation PLC (PRTA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 29 at 4:43 PM
americanbankingnews.com logoInsider Selling: Prothena Corporation PLC (NASDAQ:PRTA) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 19 at 7:38 PM
americanbankingnews.com logo Brokerages Anticipate Prothena Corporation PLC (NASDAQ:PRTA) Will Announce Quarterly Sales of $12.87 Million
www.americanbankingnews.com - July 16 at 10:48 AM
americanbankingnews.com logoZacks: Analysts Expect Prothena Corporation PLC (NASDAQ:PRTA) Will Announce Earnings of -$1.02 Per Share
www.americanbankingnews.com - July 14 at 11:21 AM
americanbankingnews.com logoJefferies Group Weighs in on Prothena Corporation PLC's Q2 2017 Earnings (NASDAQ:PRTA)
www.americanbankingnews.com - July 13 at 10:50 AM
americanbankingnews.com logoProthena Corporation PLC (NASDAQ:PRTA) Now Covered by Jefferies Group LLC
www.americanbankingnews.com - July 10 at 5:26 PM
americanbankingnews.com logoDennis J. Selkoe Sells 3,500 Shares of Prothena Corporation PLC (PRTA) Stock
www.americanbankingnews.com - July 7 at 8:18 PM
nasdaq.com logoCommit To Purchase Prothena Corp At $45, Earn 15% Annualized Using Options
www.nasdaq.com - July 7 at 8:17 AM
americanbankingnews.com logoProthena Corporation PLC (NASDAQ:PRTA) Rating Reiterated by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 6 at 11:02 AM
globenewswire.com logoProthena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease
globenewswire.com - July 6 at 8:05 AM
finanznachrichten.de logoPROTHENA CORPORATION PLC
www.finanznachrichten.de - July 6 at 8:05 AM
streetinsider.com logoProthena Corp. (PRTA) Commences Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease
www.streetinsider.com - July 6 at 8:05 AM
finance.yahoo.com logoProthena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease
finance.yahoo.com - July 6 at 8:05 AM
americanbankingnews.com logoProthena Corporation PLC (NASDAQ:PRTA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 4 at 5:20 PM
finance.yahoo.com logoCarson Block Shorts Prothena on Drug Questions
finance.yahoo.com - June 30 at 4:25 AM
finance.yahoo.com logoFeared short seller Carson Block's next target is this biotech stock
finance.yahoo.com - June 30 at 4:25 AM
finance.yahoo.com logoMuddy Waters Shorts Prothena On Doubts Of Drug Candidate's Efficacy
finance.yahoo.com - June 30 at 4:25 AM
finance.yahoo.com logoProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : June 28, 2017
finance.yahoo.com - June 29 at 6:16 AM
nasdaq.com logoPRTA Crosses Below Key Moving Average Level
www.nasdaq.com - June 27 at 7:26 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Prothena Corporation PLC's FY2018 Earnings (PRTA)
www.americanbankingnews.com - June 26 at 8:00 AM
americanbankingnews.com logo$8.52 Million in Sales Expected for Prothena Corporation PLC (PRTA) This Quarter
www.americanbankingnews.com - June 22 at 1:04 PM
americanbankingnews.com logo Analysts Anticipate Prothena Corporation PLC (PRTA) to Post -$1.09 Earnings Per Share
www.americanbankingnews.com - June 20 at 10:00 AM
finance.yahoo.com logoETFs with exposure to Prothena Corp. Plc : June 15, 2017
finance.yahoo.com - June 16 at 9:04 AM
finance.yahoo.com logoProthena Corp. Plc – Value Analysis (NASDAQ:PRTA) : June 15, 2017
finance.yahoo.com - June 16 at 9:04 AM
americanbankingnews.com logoProthena Corporation PLC (PRTA) Lifted to Hold at ValuEngine
www.americanbankingnews.com - June 15 at 8:10 PM
finance.yahoo.com logoProthena (PRTA) Down 5.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 14 at 8:37 AM
finance.yahoo.com logoProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : June 14, 2017
finance.yahoo.com - June 14 at 8:37 AM

Social

Chart

Prothena Corporation PLC (PRTA) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff